Norges Bank Makes New $18.36 Million Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Norges Bank bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTXFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,075,037 shares of the biopharmaceutical company’s stock, valued at approximately $18,362,000. Norges Bank owned 0.71% of TG Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TGTX. NBC Securities Inc. bought a new stake in shares of TG Therapeutics during the third quarter valued at approximately $58,000. Assenagon Asset Management S.A. bought a new stake in shares of TG Therapeutics during the third quarter valued at approximately $1,219,000. Arizona State Retirement System raised its position in shares of TG Therapeutics by 3.5% during the third quarter. Arizona State Retirement System now owns 40,411 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 1,356 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in shares of TG Therapeutics during the third quarter valued at approximately $132,000. Finally, Swiss National Bank raised its position in shares of TG Therapeutics by 3.1% during the third quarter. Swiss National Bank now owns 312,000 shares of the biopharmaceutical company’s stock valued at $2,608,000 after buying an additional 9,300 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

Insider Buying and Selling

In related news, Director Laurence N. Charney sold 22,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the sale, the director now directly owns 215,229 shares of the company’s stock, valued at $3,437,207.13. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 9.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on TGTX shares. StockNews.com cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. HC Wainwright lifted their price objective on shares of TG Therapeutics from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. LADENBURG THALM/SH SH lifted their price objective on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $25.00 price objective on shares of TG Therapeutics in a research note on Thursday, April 18th. Finally, The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and an average price target of $29.83.

Read Our Latest Analysis on TGTX

TG Therapeutics Stock Up 0.2 %

Shares of TGTX opened at $16.33 on Tuesday. The firm has a market capitalization of $2.52 billion, a P/E ratio of 71.00 and a beta of 2.30. TG Therapeutics, Inc. has a 12-month low of $6.46 and a 12-month high of $29.32. The company has a current ratio of 3.62, a quick ratio of 2.84 and a debt-to-equity ratio of 0.63. The firm has a fifty day moving average price of $15.56 and a 200-day moving average price of $15.67.

TG Therapeutics (NASDAQ:TGTXGet Free Report) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The company had revenue of $63.47 million for the quarter, compared to analysts’ expectations of $54.60 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 31.34%. The firm’s revenue for the quarter was up 713.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.28) earnings per share. Equities research analysts expect that TG Therapeutics, Inc. will post -0.01 earnings per share for the current year.

TG Therapeutics Company Profile

(Free Report)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Featured Articles

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.